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Purpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT)
and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical
relapse-free survival (cRFS) of this combined treatment. Methods. 126 patients with high-risk PC (T3-4 or PSA > 20 ng/mL or
Gleason 8–10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical
relapse was defined as PSA nadir +2 ng/mL. Clinical relapse was defined as local failure or metastases. Results. The incidence of
late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively. Five-year bRFS and cRFS were 73% and 86%
respectively. AD was a significant predictor of bRFS (P = 0.001) and cRFS (P = 0.01). Conclusion. High-dose IMRT and AD for
high-risk PC oﬀers excellent biochemical and clinical control with low toxicity.
1. Introduction
The of PSA screening has resulted in an increased detection
rate of prostate cancer (PC) with stage migration towards
lower-stage prostate cancer (PC). Nevertheless, still 12% of
the patients with PC will have locally advanced (T3-4 N0M0
or Tx N1 M0) or metastatic disease at diagnosis [1]. More
aggressive therapies are indicated for these patients as they
are at increased risk of PC death [2]. External beam radio-
therapy (EBRT) is one of the standard treatment options
of choice for those patients. However, when conventional
low-dose (<72Gy) EBRT is applied in patients with clinical
stage T3-T4 PC, local recurrence rates mount to 30% at 10
years [3]. Improvement of local control is important as local
failure is directly correlated with distant metastasis [3, 4]
and survival [5]. Extensive evidence exists that high-dose
radiotherapy (dose≥ 74Gy) is superior to conventional dose
radiotherapy (dose 64–70Gy) [6–8]. For high-risk patients,
an increase in 5-year biochemical relapse-free survival
(bRFS) of 19% has been reported when increasing the dose
from 70Gy to 80Gy [9]. Zelefsky et al. demonstrated that
the rate of positive biopsies after EBRT dropped with 30%
when the dose was increased from <70.2Gy to >81Gy [10].
With modern radiotherapy techniques, such as intensity-
modulated radiotherapy (IMRT), dose escalation can safely
be performed [11]. Randomized trials support the combined
use of EBRT and androgen deprivation (AD) with superior
disease-specific and overall survival outcomes in patients
with locally advanced-stage or high-risk disease [12, 13].
Based on the above-mentioned data, patients with high-
risk PC are treated at our institute with high-dose IMRT and
24–36 months of AD. In this paper, we report on
(i) late gastrointestinal (GI) and genitourinary (GU)
toxicity,
(ii) biochemical control,
(iii) clinical control
of this combined treatment modality.
2. Material and Methods
2.1. Patients. Between December 1998 and March 2011,
604 patients were treated with IMRT as primary therapy
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for prostate cancer at Ghent University Hospital (GUH).
Over time 3 diﬀerent dose levels were initiated as has been
previously reported [14, 15]. Between 1996 and 2001,
2 prescriptions were launched: 74Gy (74R72) and 76Gy
(76R74) as median dose to the planning target volume (PTV)
of the prostate + seminal vesicles with a hard constraint on
maximal rectal dose of 72 and 74Gy, respectively. In 2002, a
third dose escalation level was initiated, in which we treated
the PTV to 78Gy while keeping the maximal rectal dose at
76Gy (78R76).
High-risk PC was defined as PC with one of the following
characteristics: clinical T3-4 or PSA >20 ng/mL or Gleason
8–10. Patients with pN1 or cN1 disease were treated within
another study protocol [16] and consequently not included
in this study. In total 43% of the patients fulfilled these
criteria. Only patients with high-risk PC and a minimal
followup of 24 months were considered for this report
resulting in a study population of 126 patients: 21 patients
in the 74R72 group, 19 patients in the 76R74 group, and 86
patients in the 78R76 group.
T stage was determined by digital rectal examination
supplemented with magnetic resonance (MR) imaging data.
The 2002 American Joint Commission on Cancer staging
was used [17]. Lymph node staging was done by CT scan
in all cases and in 54 cases by pelvic lymphadenectomy.
All patients underwent bone scintigraphy. Except for 10
patients, who refused AD, a luteinizing-hormone releasing
hormone (LHRH) analogue was initiated for a period of 24–
36 months.
A fixed questionnaire was used to register the medical
history and pretreatment GU and GI symptoms of each
patient.
2.2. Treatment Planning. Details on pretreatment imaging,
delineation of clinical target volume (CTV) and organs at
risk, expansion of CTV to PTV, treatment planning, criteria
for plan acceptance, leaf position optimization, patient
preparation, and treatment delivery can be found in our
previous work [14]. In brief, the CTV consisted of the
prostate and seminal vesicles. None of the patients received
elective lymph node irradiation. The PTV was created using
a 3-dimensional, isotropic expansion of the CTV of 7mm.
The rectal wall (excluding air and faeces), sigmoid colon,
bladder, small bowel, and femoral heads were delineated as
organs at risk. Patients were treated with empty rectum and
comfortably filled bladder.
The dose was prescribed as the median dose to the
PTV. Treatment was delivered using 18 MV photons of an
Elekta linear accelerator (Crawley, UK) equipped with a
multileaf collimator (MLC) and able to deliver IMRT in a
step-and-shoot mode. Since 2009, patients were also treated
on a Clinac ix (Varian Medical Systems, Palo Alto, Calif,
USA). Until 2009, 3 beams with gantry angles 0◦, 116◦, and
244◦ were used [8]. Thereafter, planning was performed with
7 beams (gantry angles: 0◦, 52◦, 103◦, 154◦, 206◦, 257◦, and
308◦) or with single arc therapy (1 full arc counter clockwise)
[18]. First, a fixed couch height and portal imaging
procedure (Elekta electronic portal imaging device) was used
to correct patient positioning. Thereafter, an ultrasound-
based (SonArray, Zmed, Ashland, USA), prostate positioning
was added to correct for prostate positioning. Since 2009,
positioning is performed by daily kilovoltage cone beam
CT.
2.3. Followup. Patients were seen every 3 months for the first
year, biannually until 5 years, and yearly thereafter. A fixed
toxicity questionnaire was fulfilled at each visit.
2.4. End Points. Late toxicity was defined as any increase of
any GI or GU toxicity lasting more than 3 months after
cessation of IMRT or occurring for the first time later
than 3 months after the end of IMRT. The grade of late
GI (Table 1(a)) and GU toxicity (Table 1(b)) was scored
according to an in-house developed scoring system based on
the RTOG, SOMA/LENT, and CTC toxicity scorings system
[19, 20]. For each symptom, the maximal toxicity score was
registered.
Biochemical relapse was defined according to the Phoenix
consensus definition, that is, PSA nadir +2 ng/mL [21].
Clinical relapse was defined as local failure (determined
on prostate biopsies) or metastases (both lymph node and
haematogenous metastasis) detected on imaging (18F-fluor-
odeoxyglucose positron-emitting tomography/computed to-
mography and bone scan) performed at the time of biochem-
ical relapse.
Kaplan-Meier statistics were used to report on 5-year
bRFS and clinical relapse-free survival (cRFS). Univariate
analysis (log-rank test) was used to examine the predictive
value of the dose prescription group, Gleason score group
(Gleason 6 versus 7 versus 8–10), cT (T1-T2-T3-T4), PSA
(PSA < 10 ng/mL versus PSA: 10–20 ng/mL versus PSA ≥
20), staging by lymphadenectomy (pN0 versus pNx), and
use of AD. Multivariate analysis was performed using Cox
regression analysis.
Using Chi-square statistics, the baseline patient-related
risk factors were compared for the diﬀerent prescription
groups. A P value of < 0.05 was considered statistically
significant.
Statistical analysis was performed with SPSS version 15.0
software (Chicago, ILL, USA).
3. Results
Patient characteristics and planning parameters are shown
in Tables 2 and 3, respectively. Significantly fewer patients
received AD in prescription group 74R72 (P = 0.002).
Except for follow-up time, all other parameters were equally
balanced between the diﬀerent prescription groups. Median
followup was 48 months.
3.1. Late Toxicity. Late toxicity was mild. No patient devel-
oped grade 4 GI or GU toxicity. The incidence of grade 1–3
late GI and GU toxicity is presented in Table 4. The crude
incidence of late grade 3 GI and GU toxicity was 2 and 6%,
respectively. Dose escalation did not result in increased GI or
GU toxicity.
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Table 1: (a) The in-house developed Gastrointestinal toxicity scale, (b) The in-house developed Genitourinary toxicity scale.
(a)
GI Grade 1 Grade 2 Grade 3 Grade 4
Abdominal cramps Present, no therapy
Peroral therapy, for example,
Spasmolytic
IV therapy Surgery
Diarrhea Present, no therapy
Peroral therapy, for example,
loperamide
IV therapy Surgery
Frequency Present, no therapy
Peroral therapy, for example,
loperamide
IV therapy —
Mucus loss Present, no therapy Need hygienic pads
Continuous, invasive
therapy
Surgery
Red blood loss
No therapy,
frequency < 3x/week
Frequency ≥ 3x/week
Invasive therapy
needed, for example,
laser coagulation
Transfusion
need, surgery
Urgency Present, no therapy Peroral therapy IV therapy —
Incontinence Present, no therapy Need hygienic pads (≤2/day) Need hygienic pads
(>2/day)
Surgery
Anal pain Present, no therapy
Local anesthetic for example,
Xylogel
Narcotic analgetica Surgery
(b)
GU Grade 1 Grade 2 Grade 3 Grade 4
Nocturia
Twice pretherapy,
2-3 times
4–6 times (<1x hour)
>6 times (more
frequently than
hourly)
—
Frequency
Once/2 h, twice
pretherapy
Once/1 h
Once/0.5 h (more
frequent than hourly)
—
Hematuria Microscopic Intermittent/moderate
Frequent, gross
hematuria/minor
surgery needed
(coagulation)
Hemorrhagic
cystitis
requiring
transfusion/
ulceration/
necrosis
Dysuria
Slight, no
medication
Moderate, requiring local
anesthetic (including bladder
spasm)
Dysuria, regular and
frequent narcotics
needed (including
bladder spasm and
pelvis pain)/severe/
stenosis/TUR or
dilatation
Bladder
obstruction
not
secondary to
clot passage
Urgency
Slight, no
medication
Moderate, requiring local
anesthetic (including bladder
spasm)
Severe requiring local
anesthetic
—
Incontinence <weekly episodes <daily episodes
Pads/undergarments/
day
Refractory
3.2. Biochemical Relapse. Twenty-eight patients experienced
biochemical relapse resulting in a 5-year bRFS of 73% for
the whole group. T stage, addition of lymphadenectomy,
pretreatment PSA, and Gleason score were not significantly
correlated with bRFS. Although not significant, there was a
strong trend towards better 5-year bRFS rates with higher
radiotherapy doses (52%, 83%, and 76% for 74R72, 76R74,
and 78R76, resp., P = 0.051) (Figure 1).
The association of AD was significantly correlated with
5-year bRFS (77% versus 30%; P < 0.001) (Figure 2).
In multivariate analysis AD remained a significant pre-
dictor of bRFS (P = 0.001).
3.3. Clinical Relapse. Fourteen patients had a clinical relapse.
Clinical relapses occurred in the lymph nodes (N = 4), bone
(n = 9), or prostate (n = 2). One patient had both lymph
node and bone metastases at time of clinical relapse. The 5-
year cRFS was 86%. T stage, addition of lymphadenectomy,
pretreatment PSA, and Gleason did not significantly influ-
ence cRFS. There was a significant correlation between 5-year
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Table 2: Patient’s characteristics for all patients and according to prescription group.
Characteristic Prescription group
All (n = 126) 74R72 (n = 21) 76R74 (n = 19) 78R76 (n = 86)
Age (years) 66 (41–79) 62 (51–76) 65 (53–75) 66 (41–79)
Followup (months) 48 (24–132) 60 (24–132) 84 (24–108) 45 (24–96)
PSA level (ng/mL) 19 (4–302) 26 (8–150) 20 (4–90) 14 (4–302)
Gleason score
2–6 49 (39) 9 (43) 11 (58) 29 (34)
7 (3 + 4)/(4 + 3) 37 (29) 7 (33) 5 (26) 25 (29)
8–10 39 (31) 5 (24) 3 (16) 31 (36)
Unknown 1 (1) — — 1 (1)
Tumor stage
T1 17 (13) 2 (10) 4 (20) 11 (12)
T2 40 (32) 9 (43) 2 (11) 29 (34)
T3 60 (48) 7 (33) 12 (64) 40 (48)
T4 9 (7) 3 (14) 1 (5) 6 (6)
Node stage
pN0 54 (43) 9 (43) 3 (16) 42 (49)
Androgen deprivation
Yes 116 (92) 14 (67) 17 (89) 85 (99)
No 10 (8) 7 (33) 2 (11) 1 (1)
Table 3: Planning parameters for all patients and according to prescription. CTV: clinical target volume; Gy: Gray; PTV: planning target
volume; R40 and R60: percentage of the rectal volume receiving a dose of 40 and 60 Gy, respectively; Rmean: mean dose to the rectum, Bmax
and Bmean: maximal and mean dose to the bladder.
All (n = 126) 74R72 (n = 21) 76R74 (n = 19) 78R76 (n = 86)
CTV volume (cc) 61 (22–180) 86 (26–146) 68 (28–112) 53 (22–180)
Minimum CTV dose (Gy) 73 (55–77) 68 (55–70) 72 (67–74) 73 (68–77)
Median CTV dose (Gy) 78 (72–83) 76 (72–78) 77 (72–82) 79 (74–83)
PTV volume (cc) 155 (48–347) 250 (121–347) 226 (100–289) 123 (48–296)
Minimum PTV dose (Gy) 69 (52–73) 65 (52–68) 67 (65–70) 69 (64–73)
Median PTV dose (Gy) 77 (70–82) 74 (70–76) 75 (72–80) 78 (75–82)
R40 71 (30–97) 90 (88–90) 87 (57–97) 68 (30–94)
R60 43 (22–90) 64 (29–90) 54 (26–69) 40 (22–63)
Rmean 51 (33–71) 57 (39–65) 54 (37–62) 49 (33–71)
Bmax 79 (72–82) 78 (72–79) 79 (76–82) 79 (76–82)
Bmean 43 (13–72) 49 (19–68) 58 (16–65) 40 (13–72)
Table 4: Late gastrointestinal and genitourinary toxicity for all patients and according to prescription group.
Late GI toxicity
All (n = 126) 74R72 (n = 21) 76R74 (n = 19) 78R76 (n = 86)
Grade 1 52 (41) 9 (43) 8 (42) 35 (41)
Grade 2 20 (16) 6 (29) 2 (11) 12 (14)
Grade 3 2 (2) 0 1 (5) 1 (1)
Late GU toxicity
All (n = 126) 74R72 (n = 21) 76R74 (n = 19) 78R76 (n = 86)
Grade 1 55 (44) 11 (52) 7 (37) 37 (43)
Grade 2 26 (21) 1 (5) 4 (21) 21 (24)
Grade 3 7 (6) 3 (14) 1 (5) 3 (4)
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Figure 1: Biochemical relapse-free survival according to prescrip-
tion group.
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Figure 2: Biochemical relapse-free survival for patients treated with
high-dose IMRT with or without androgen deprivation.
cRFS and dose (67%, 83%, and 90% for 74R72, 76R74, and
78R76, resp.; P = 0.04) as well as between 5-year cRFS and
AD (91% versus 30%; P < 0.001).
The only significant predictor of cRFS in multivariate
analysis was AD (P = 0.01).
4. Discussion
Multiple treatment options are available for patients with
high-risk PC such as surgery, high-dose EBRT, and AD.
AD has been the primary treatment for patients with
high-risk PC for many years. Although the response rate is
high, AD alone is not a curative therapy and has important
side eﬀects. A recently published randomized trial confirmed
that the addition of EBRT to AD resulted in a significant
improvement in overall survival when compared to AD [22].
Merglen et al. claimed that surgery, as a single treatment,
oﬀers the best 10-year survival rates for T1–T3 PC patients
when compared to EBRT without AD, particularly for
younger patients and patients with poorly diﬀerentiated
tumours [23]. However this study has major shortcomings
such as the lack of information on radiation dose and
an imbalance between the surgery and radiotherapy group
concerning Gleason score and PSA [23]. Moreover, 10-
year overall survival and PC-specific survival was better for
patients treated with EBRT and AD versus prostatectomy
alone (80% versus 69% and 87% versus 83% for overall
survival and PC-specific survival, resp.).
Akakura et al. randomized patients between radical
prostatectomy and low-dose EBRT (60–70Gy) both com-
bined with AD. The 10-year overall survival rates were better
for the surgery group, although not statistically significant
[24]. Recently the long-term outcome of patients with high-
risk PC was reported comparing survival after RP and EBRT
± AD. The authors concluded that RP and EBRT + AD
provided similar long-term cancer control for patients with
high-risk PC [25]. In a retrospective matched case analysis,
RP, brachytherapy, and multimodality radiotherapy (i.e.,
EBRT with brachytherapy boost and AD) were compared.
Significantly improved bRFS at 4 years was reported with
multimodality radiotherapy (multimodality radiotherapy:
72%, brachytherapy: 25%, and RP: 53%, P < 0.001) [26].
In the absence of randomized trials and based on published
data surgery, whether or not combined with adjuvant
radiotherapy and high-dose radiotherapy combined with
AD should be considered as equally eﬀective in this patient
group.
In the published series, clinical or biochemical relapse
is still observed in more than a quarter of the patients 5
years after treatment. Extensive evidence exists that high-
dose radiotherapy (dose≥ 74Gy) is superior to conventional
dose radiotherapy (dose 64–70Gy). Zelefsky et al. reported
long-term results after high-dose radiotherapy for T3 PC.
For patients treated with high doses (81Gy) combined with
AD, 5- and 10-year PSA relapse-free survival was 77% and
52% for T3a stage and 53% and 49% for T3b stage PC.
Dose was an important predictor of improved biochemical
control. With higher doses (≥ 81Gy), 5- and 10-year local
progression-free survival of 96% and 88% is reported [27].
Our data confirm these encouraging figures with 5-year
bRFS and cRFS rates of 73% and 86%, respectively. In
contrast with the study of Zelefsky et al., we were not able
to detect a significant dose-response relationship. Although
there was a significant relation between prescription dose
and cRFS and a strong trend towards better bRFS with
higher doses, this was no longer present in multivariate
analysis. These data must be interpreted with caution due
to the small number of patients in the lowest prescription
group as well as the imbalance between the patients receiving
AD in the diﬀerent prescription groups. Significantly fewer
patients in prescription group 74R72 received AD. The role
of concomitant AD was unequivocally confirmed in our
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study with a significant impact on bRFS and cRFS in uni-
and multivariate analysis.
Dose escalation to the prostate is only defendable if both
radiotherapy-induced GI and GU toxicities remain accept-
able. There is level 1 evidence that toxicity increases with
dose when conventional or conformal radiation technologies
are used [11]. The implementation of new radiotherapy
technologies has resulted in low GI toxicity rates. Even with
dose escalation to the prostate late grade ≥3 GI toxicity is
rare with modern radiotherapy techniques with incidence
rates of <1% [28] to 2% [29] and 5% [30]. On the contrary,
GU toxicity is more frequent with incidence rates of late
grade ≥ 3 GU toxicity of 13% [30]. The reported toxicity
rates in our study (grade 3 GI: 2% and grade 3 GU: 6%)
are comparable with published data and confirm that high-
dose IMRT combined with AD can safely be delivered. Dose
escalation did not result in higher toxicity rates in our
study probably as a result of the implementation of a direct
aperture and weight optimization (SOWAT) in the higher
prescription groups. In a planning study, the use of SOWAT
resulted in a reduction of the rectal complication probability
by lowering the physical dose to rectal volumes without
compromising the dose to the prostate. The present paper
confirms that SOWAT is clinically relevant andmakes further
dose escalation possible without increasing rectal or urinary
toxicity.
The role of prophylactic pelvic irradiation for patients
with high-risk PC is still under debate. Two large randomised
trials were published with opposite results. The Radiation
Therapy Oncology Group (RTOG) 9413 trial favours pelvic
radiotherapy [31]. A significant 7% improvement in the 4-
year progression-free survival (PFS) rate was reported when
patients were treated with a combination of neoadjuvant +
concurrent AD and pelvic EBRT compared with prostate-
alone EBRT for patients with intermediate and high-risk
PC. However, there was no significant benefit in overall or
distant metastases-free survival. Importantly, an increase in
late grade 2 and 3 toxicities was noted [31].
The GETUG randomised trial on the contrary failed to
show diﬀerences in PFS [32].
There are 2 important shortcomings of these “older”
trials that might have influenced the results: at first, the
radiotherapy dose to the prostate was low (70Gy). Secondly
there might have been an insuﬃcient coverage of the pelvic
lymph nodes regions at risk. The role of dose was evaluated
in the GETUG trial in which they failed to show a significant
diﬀerence in the groups receiving < or ≥ 70Gy at the level of
the prostate, which is, after all, still a low dose [32].
A large retrospective study with high-dose brachytherapy
also failed to demonstrate a benefit for pelvic irradiation,
suggesting that dose escalation to the prostate rather than
pelvic radiotherapy is beneficial [33].
A new phase III trial (RTOG 0924) will soon be opened
for enrolment further addressing the issue on prophy-
lactic pelvic irradiation. The RTOG 0924 is a phase III
trial for intermediate and favourable high-risk PC patients
randomizing between androgen deprivation and high-dose
radiotherapy with or without whole pelvic radiotherapy.
PIVOTAL is another multicentre study for patients with
locally advanced PC randomising between high-dose IMRT
to the prostate ± pelvic lymph nodes. The endpoints of the
study are toxicity, quality of life, and disease outcome. Patient
recruitment is now ongoing.
In the absence of the results of these “modern” phase III
trials, the implementation of pelvic irradiation is not current
standard and left at the discretion of the radiotherapists.
In our study only 4 patients had a clinical relapse in the
lymph nodes making the omission of prophylactic pelvic
radiotherapy defendable certainly when taking into account
the increased risk of GI toxicity as a result of irradiation of
larger volumes of small bowel, even with modern radiother-
apy techniques.
Some recent data suggest that the patient’s outcome is
positively influenced by staging lymphadenectomy. However,
the exact impact of an extended lymphadenectomy on
patient outcomes has not yet been clearly determined.
Recently, Masterson et al. reported that a higher number of
nodes removed correlated significantly with bRFS in men
without nodal involvement [34] probably as a result of elim-
ination of micrometastases that are not detected by routine
histological examination. Joslyn and Konety [35] published
similar results. Patients included in this study were treated
since 1996. At that time staging lymphadenectomies were not
routinely performed. Consequently only few patients in our
study received a staging pelvic lymphadenectomy. Moreover,
there is an important lack of information on extent of
lymphadenectomy and number of lymph nodes removed. In
our study 3 of the 4 patients presenting with lymph node
relapse did not have previous lymphadenectomy.
5. Conclusion
High-dose IMRT and AD for high-risk PC oﬀers excellent
biochemical and clinical control with low toxicity.
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